BCL2 and B-cell chronic lymphocytic leukemia: The selective Bcl-2 inhibitor Venetoclax (ABT-199) was the first compound approved for treatment of chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML) [4,5,6].